Table 3.

Results of two Linear Mixed-Effect Models exploring predictors of Absolute Neutrophil Count.

	Base Model (Clozapine Dose & Levels)			Base Model + PGx Predictors
	Estimate	Std. Error	P value	Estimate	Std. Error	P value
Daily Dose	0.133	0.034	1.08 × 10−4	0.095	0.043	0.028
[Clozapine]	−0.166	0.054	0.002	−0.158	0.065	0.015
[Norclozapine]	0.219	0.055	6.06 × 10−5	0.225	0.065	6.15 × 10−4
TDS	0.039	0.023	0.094	0.058	0.029	0.044
Sex (Male)	−0.110	0.089	0.218	−0.078	0.114	0.495
Age	0.220	0.040	6.56 × 10−8	0.213	0.051	4.03 × 10−5
Age2	−0.067	0.038	0.078	−0.072	0.048	0.140
CYP1A2 Activity Score				0.155	0.056	0.006
rs2472297_T				0.008	0.057	0.887
rs61750900_T				0.043	0.049	0.382
rs2011425_G				−0.008	0.052	0.872
rs1126545_T				−0.020	0.051	0.701
Random Effects
σ2	0.748			0.713
τ00 LUIN	0.883			0.965
ICC	0.541			0.575
N LUIN	811			517
Observations	2362			1563
Marginal R2 / Conditional R2	0.052 / 0.565			0.060 / 0.601

Results of two Linear Mixed-Effect Models exploring predictors of Absolute Neutrophil Count (ANC). Standardised regression coefficients are reported alongside standard error and p values estimated using the lmerTest package.

PGx Pharmacogenomic, TDS Time between Dose and Sample, [Clozapine] Clozapine plasma concentration, [Norclozapine] Norclozapine plasma concentration, LUIN Participant Identifier used in CLOZUK3, σ2 Residual Variance, ICC Intraclass Correlation Coefficient, τ00 LUIN Random Intercept Variance, N LUIN Number of participants.